Tilray Inc (NASDAQ:TLRY) Jupiter Research Provides A Production Update Despite The Emergence Of Coronavirus

Investors thought that the coronavirus scourge would impact the way Tilray Inc (NASDAQ:TLRY) goes about its operations significantly. That doesn’t seem to be the case considering that the business guru has unveiled its production update despite the impact of the deadly virus.

Coronavirus did not shake up matters as was projected

The world was not prepared for Coronavirus, and that is for sure. There has been a lot of grappling in the dark in a bid to find the cure for the ailment. The US government has been at the frontline in trying to seek out ways to eliminate the virus, which has affected a great deal of the world economies.

China is one of the most affected by the deadly disease, and many lives have been lost amidst efforts to curb it. The US president recently challenged policymakers, health and wellness experts, and other parties to put their heads together. The US leader thought that working as a unit would be more productive as compared to the idea of the different parties working separately to find vaccines.

Scatterday’s take

Tilray provides updates about Jupiter Research, which happens to be one of its subsidiaries. According to the business guru, the subsidiary will soon be going back online despite the effects of the delays resulting from the Chinese New Year. The Coronavirus had also raised major concerns, but it is a good thing the business hasn’t been affected immensely.

The CEO of TILT, who also happens to be its founder Mark Scatterday has spoken elaborately regarding the recent developments. The official discloses that they are focused on doing everything possible to take care of the needs of their loyal customers. He outlines that they usually find it frustrating anytime they have to halt production activities over some inevitable conditions.

Scatterday applauds the company’s sales team for its dedication. According to him, the working person has been receiving orders and working on them promptly. Customers have always been happy seeing how the company fulfils their requests on time.

The warehouse of Jupiter lies in Phoenix, Arizona. Reports indicate that it has the sort of inventory that makes it possible to fulfill the wide-ranging customer orders.


Tilray Inc (NASDAQ:TLRY) Lays Off A Fraction Of Its Workforce In Restructuring Efforts

Tilray Inc (NASDAQ:TLRY) has communicated several of the changes it is making to several financial news outlets. The business guru made its statement via email after the close of the market on Tuesday.

Laying off employees

This cannabis producer lay off about 10% of its workers in a bid to cut down on its operational costs. This global restructuring effort is being looked at as a way for the company to ease the tension among its shareholders. The investors in the company have been closely monitoring its performance, with some expressing satisfaction with the turn of events.

The cutting down of the company’s workforce is one of the many moves the company will be resorting to in a bid to regain stability.

November was an important month that considering that it was the point the shareholders learned about the company’s operating costs for 2019. Such instances have always been important for investors who decide about the best time to make investments.

Shareholders and the concerned parties aware of the company’s moves have shown mixed reactions. There is a section that sides with the company saying that the decision was necessary. However, there is the second lot that belives the company should have resorted to something other than terminating the services of the dedicated workers.

Opinions expressed

Tilray has been quick to defend its decision outlining that it was in the best interest of the company and the shareholders. According to it, there were always times that called for the making of some difficult choices and that this was one of those moments.

Analysts following closely on the matter have also aired out their views. They take the strong stand that the business guru was trying its best to soften the landing, and that is in line with the earnings reports.

The earnings were not impressive for the company, and that is the reason it took a drastic measure. Most of the analysts are not in support of the decision that led to about 140 employees losing their employment. They think that it paints the company in a bad light and believes there were better alternatives that the company should have looked at.


Searching for Big Money in the Cannabis Patch (TLRY, TMGI, ACB, CURLF)

The cannabis bear has been roaring for a year now. But 2020 has sparked a sense of renewed hope for the patch, and we wanted to take a look at a few possible ideas for taking advantage, and pass our judgement on each in turn: Tilray Inc (NASDAQ:TLRY), Marquie Group Inc (OTCMKTS:TMGI), Aurora Cannabis Inc (NYSE:ACB), Curaleaf Holdings Inc (OTCMKTS:CURLF).

Tilray Inc (NASDAQ:TLRY) engages in the research, cultivation, processing, and distribution of medical cannabis. That said, it has been trashed by the market since topping its squeeze in September 2018 near $300. The reason for all the pain is that the company is running out of money because of how expensive it is to service its debt.

That’s a deadly conundrum for a company in a commodity market – which is the best way to think about cannabis and cannabis-related markets.

The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada.

According to the company’s IPO announcement, “Tilray, Inc., a vertically-integrated and federally-licensed cannabis cultivator, processor and distributor, today announced the pricing of its initial public offering of 9,000,000 shares of Class 2 common stock. 6,524,000 shares of Class 2 common stock will be offered in the United States and certain other countries except Canada at a price to the public of US$17.00 per share for a total offering size of US$110,908,000 and 2,476,000 shares of Class 2 common stock, which we refer to as Subordinate Voting Shares, will be offered in Canada and certain other countries except the United States at a price to the public of CAD$22.451 per share for a total offering size of CAD$55,586,200. Based on current exchange rate1, the total combined offering size is approximately US$153,000,000.00.”

One of its key subsidiaries is High Park, which was launched to produce and distribute world-class cannabis brands and products for the Canadian market. Based in Toronto and led by a team with deep experience in cannabis and global consumer brands, High Park has secured the exclusive rights to produce and distribute a broad-based portfolio of cannabis brands and products in Canada, subject to applicable laws and regulations.

In addition, High Park has developed new brands and products for the Canadian market. Upon the coming into force of federal legalization of cannabis for adult-use and corresponding provincial legislation, High Park anticipates fulfilling adult-use supply agreements and purchase orders in Quebec, Ontario, British Columbia, Manitoba, Nova Scotia, Prince Edward Island, Northwest Territories and Yukon on October 17, 2018.

Even in light of this news, TLRY hasn’t really done much of anything over the past week, with shares logging no net movement over that period. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -8%. 

Tilray Inc (NASDAQ:TLRY) pulled in sales of $51.1M in its last reported quarterly financials, representing top line growth of 408.6%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($122.4M against $130.2M, respectively). But the debt-servicing costs are the problem here, as is the company’s lack of competitive traction. Pass.

Marquie Group Inc (OTCMKTS:TMGI) is a clear emerging leadership play in the CBD space, so it deserves acknowledgement here in this group. 

The company just put out word that it is setting to launch its own branded line of premium CBD tinctures, which could be huge given that the company boasts undeniable expertise in attacking the market for women aged 35-49 – which also happens to be the biggest demographic component of the CBD products marketplace.

While the stock hasn’t yet started to gain traction with traders, the company boasts top talent in the health and beauty space coming together with the concept of the huge growth anticipated in CBD. Much of that promise springs from its leader, Jacquie Carter Angell, who has established an internationally recognized personal brand as a beauty expert, appearing in television, radio, magazine, newspaper and media events around the world. 

According to the company, during that time, she has partnered with celebrities, Olympic athletes, doctors, nutritionists and Nobel Prize laureates in brand-building and marketing health and beauty products to women in more than 90 countries. “The CBD market has grown exponentially, evolving from the virtually unknown, to a marketplace where consumer perception and expectations are on the rise. A lesser-known fact is that the largest consumer for CBD products is women between 35-49 years of age,” commented Jacquie Carter Angell, President of The Marquie Group. “We have predicated the majority of the packaging, branding, marketing, and digital identity around this fact in a manner that positions Whim with far less direct niche-level competition than other CBD product brands.”

Marquie Group Inc (OTCMKTS:TMGI) bills itself as company led by former Director of Worldwide Training and Education for Herbalife Nutrition, Jacquie Carter Angell. It is a direct-to-consumer health and beauty products platform with a pipeline of innovative solutions to pervasive wellness concerns: anxiety, anti-aging, low energy, sleeplessness, and stress that use advanced formulations of plant-based, amino-acids and CBD alternatives to chemical ingredients. 

All products will feature unique formulations of top-quality ingredients meant to impart skin health that comes from improved amino-acid balance and CBD nutrition.

The Marquie Group owns and operates two businesses: Music of Your Life, Inc, the nation’s longest-running, nationally syndicated music radio network broadcast nationwide and internationally to a worldwide audience on the Internet, and Global Nutrition Experience, Inc. (GNX), an intellectual property licensing and development corporation.

Products planned for a 2020 launch include facial skin care serums, a powerful amino acid infused collagen drink and custom blended CBD tinctures each with their own potent puree of nature’s finest fruits, flowers and herbs. Each one is uniquely developed to provide optimal sleep and relaxation, mental focus and clarity or beauty and antioxidant benefits via an array of plant- based ingredients formulated to enhance one’s Inner Health and Outer Beauty.

Aurora Cannabis Inc (NYSE:ACB) has shown us a line of evidence in its strategic moves over the past 24 months to clearly signal that it wants to be a major player in the CBD boom.

For example, in 2017, the company invested in Hempco, a Vancouver-based maker of hemp-based foods, hemp fiber, and hemp nutraceuticals. Hempco also supplied Aurora with raw hemp for extracting CBD. ACB bought the rest of Hempco three months later.

The company next acquired Agropro, Europe’s largest producer, processor, and supplier of certified organic hemp and hemp products. At the same time, Aurora acquired Agropro’s sister company Borela, which processes and distributes organic hulled hemp seeds, hemp seed protein, hemp flour, and hemp seed oil.

Just after that, in late 2018, Aurora acquired ICC Labs, which claims leadership in the South American hemp CBD market, with a large-scale extraction facility that can process 150,000 kg of CBD feed annually.

That’s three big M&A moves in the past 30 months with one clear goal: to capture major market share in the CBD space. And it spans three different continent. This is a company on a mission and investors who believe in the larger growth thesis should take note now.

Aurora Cannabis Inc (NYSE:ACB) managed to rope in revenues totaling $98.9M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 416.7%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($362M against $436.4M, respectively).

Curaleaf Holdings Inc (OTCMKTS:CURLF) is another primarily cannabis name to make clear moves toward the CBD space. This is likely to be linked with its existing distribution footprint, which keeps expanding by the month.

As a case in point, the company recently announced the opening of its 28th Florida dispensary at 1435 South Tamiami Trail in Sarasota. Curaleaf has the largest cannabis dispensary footprint in the US with 51 dispensaries across the country, and continues to execute on its strategy of rapid expansion in Florida.

“We are proud to deliver upon our commitment to expand our Florida footprint, providing patients with access to Curaleaf’s premium medical cannabis products and educational resources, and serving the Sarasota community 7 days a week,” said Pablo Arizmendi-Kalb, President of Curaleaf Florida.

Curaleaf Holdings Inc (OTCMKTS:CURLF) promulgates itself as a company that operates as an integrated medical and wellness cannabis operator in the United States. 

The Company is the parent of Curaleaf, Inc., a leading vertically integrated cannabis operator in the United States. Headquartered in Wakefield, Massachusetts, Curaleaf, Inc. has a presence in 12 states. 

Curaleaf, Inc. operates 30 dispensaries, 12 cultivation sites and 9 processing sites with a focus on highly populated, limited license states, including Florida, Massachusetts, New Jersey and New York. Curaleaf, Inc. leverages its extensive research and development capabilities to distribute cannabis products in multiple formats with the highest standard for safety, effectiveness, consistent quality and customer care. Curaleaf is committed to being the industry’s leading resource in education and advancement through research and advocacy. 

Curaleaf Inc.’s Florida operations were the first in the cannabis industry to receive the Safe Quality Food certification under the Global Food Safety Initiative, setting a new standard of excellence.

Shares of the stock have powered higher over the past month, rallying roughly 23% in that time on strong overall action. 

Curaleaf Holdings Inc (OTCMKTS:CURLF) managed to rope in revenues totaling $81.6M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 192.3%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($120.8M against $98.5M).


Tilray Inc (NASDAQ:TLRY) Witnesses A Mixed Business Performance

Tilray Inc (NASDAQ:TLRY) has today disclosed details about its third-quarter sales. It was a good turn for the leading company which succeeded at beating the estimates it had projected.

A breakdown of the performance

Analysts have closely linked the remarkable performance to a recent purchase of a big hemp-company.

However, there is the dark side despite the outstanding performance. Reports indicate that the per-share loss witnessed was more drastic than expected.

The whole thing started by the company’s stock hitting a rather high notch and then fell eventually. That was after the regular trading came to a close. Analysts described the performance as a rather bumpy one for the marijuana stocks.

The impact of the changes

This company’s stock stood at about $51.1 million. This was a matter that resulted in many investors thinking deeply about investments here. The business giant outlines that the addition of the Manitoba Harvest and growth was a great move. This happens to be a hemp-food maker that is growing quite vibrant in the medical marijuana markets abroad.

Most of the investors had their eyes focused on the Wall Street projections. Matters have turned out differently since the performance this time around has beaten projected figure by a significant margin. Wall Street projections have indicated a figure of about $49.59 million.

Hemp products did quite well by recording almost $15.7 million. On the other hand, recreational weed sales stood at about $15.8 billion. The performance on the international scale was also encouraging considering the $5.7 million sales figure.

Despite all this, nothing shielded the company from the poor figures where it lost 36 cents per share in the quarter. The projections made earlier on had placed the figure at 30-cent per-share.

Tilray has been making efforts to explain these changes. According to the business giant, the higher operational costs had much to do with its quest to achieve growth. The company has been channeling resources to increase its business footprint internationally. The acquisition of the Manitoba Harvest and Natura Naturals was a costly undertaking as well. However, Tilray won’t give up on its efforts to become an industry leader and take over the markets with impact.

During the quarter, the company sold 10,848 kilograms of cannabis.


Tilray Inc (NASDAQ:TLRY) Ventures Into Ireland’s Medical Cannabis Market With GMP-Certified Cannabis Oils

Tilray Inc (NASDAQ:TLRY) recently announced that it added Ireland the list of markets where it sells its cannabis products, particularly its Good Manufacturing Practices (GMP)-certified medical marijuana oils.

The company announced on Friday last week that it imported its GMP-certified cannabis oils into the Ireland where they will be made available throughout the European country. Tilray’s expansion into the country is also courtesy of the Medical Cannabis Access Programme which was enacted by Ireland’s Department of Health to help patients gain access to medical cannabis.

“We’re proud to have the opportunity to provide patients in Ireland with access to Tilray’s standardized GMP-certified medical cannabis products,” stated Catherine Jacobson the VP of Medical and Regulatory Affairs at Tilray.

Jacobson also noted that the development represents an important step forward not only for the company but also for medical marijuana patients in Ireland.  She also added that Tilray is pleased about the growing number of countries that are making an effort to boost access to medical marijuana.

Tilray is committed to making the cannabis products available to patients in Ireland

Qualified patients will get access to Tilray’s imported cannabis products via the Access Programme as soon as local regulators provide distribution approvals. This is also great news for qualified patients because it means they will access a consistent and legal supply of the products.  Additionally, the company aims to provide timely access to GMP-certified products, thus providing patients with even more convenience.

Authorized medical marijuana patients will access medical marijuana products from Tilray within the second half of 2019. The products will be made available through a network of Irish pharmacies. The company’s Managing Director for Europe, Sascha Mielcarek stated that the company was pleased about launching its products in Ireland. It is now the 13th country to import Tilray products for sale in its market.

Tilray also plans to continue expanding its operations in Europe and the rest of the world as part of its global expansion plan. These efforts plus the fact that more countries are embracing its products means that the company is gaining significant progress as and market share in its global endeavor.


Puration Inc (OTCMKTS:PURA) Gears Up to Reach $5 Million Sales Target in 2019 through Refreshing Deals

Puration Inc (OTCMKTS:PURA) has renewed accords with Tilray Inc (NASDAQ:TLRY) and Anheuser Busch Inbev NV (NYSE:BUD) to focus on research and drive the sales. With vast experience in the cannabis beverage industry, Puration is betting big on the cannabis-infused beverages to increase sales from the present $1 million to $5 million next year.

Tilray and Anheuser Busch Each Contributes $50 Million for Research

As per the terms of the accord, both Tilray and Anheuser Busch will invest $50 million each in the research project. It is on the backdrop of the legalization of recreational cannabis in Canada in October 2018. The passing of the US Hemp Farm Act 2018 is also heating interest in cannabis by dragging in big players. Many fortune 500 beverage industry companies are pumping in money to explore the cannabis-infused beverage industry.

Puration Wins Second Order for Telluride Happy Water

After bagging the first order earlier this month, Puration has won a second order for Telluride Happy Water. The company will supply the 12 pallets to the customers in Austin, Texas.

Puration Plans to Integrate Operations of Telluride Health Company into Its Cannabis Operations

Puration has recently acquired Telluride Health Company. The company will integrate the operations of Telluride Health into its cannabis beverage business. Puration Inc has issued an online presentation to the shareholders.

A group of college students, who are active in the cannabis community, have developed The Telluride Health Company. The innovative product Telluride Happy Water improves the cannabis experience to the customers. President of Telluride Health Company, Yasmine Acebo said the company is happy to become part of Puration Inc. The company will make use of the proven experience of Puration in marketing the innovative products.

Chief Executive Officer of Puration, Brian Shibley, said the team of Telluride Health has a great unique product. There is a great demand for its products with no competitors. The company is making plans to commence the production of Telluride Happy Water, which consists of a high amount of dissolved oxygen so that it will hit the shelves by the end of this month.

Pin It on Pinterest